Glycated albumin as biomarker: Evidence and its outcomes

Glycemic control markers are important for the diagnosis and treatment of diabetes. Hemoglobin A1c (A1C) is an important marker that is mandatory in routine medical examinations; however, it is well known that it has some limitations. In this review, we focus on the limitation of A1C and introduce a relatively new marker, glycated albumin (GA), which can be used to complement A1C. First, for a better understanding of the characteristics of each marker, we sort the similarities and differences of glycemic control markers as well as the characteristics of each marker. Second, we point out the limitation of A1C, introduce GA as an alternative indicator, and discuss the limitations of GA. Finally, we summarize important evidence regarding the utility of GA. We hope that this review provides useful information that permits more effective usage of GA as well as other glycemic control markers.

Automated summary

This review discusses the importance of glycemic control markers in the diagnosis and treatment of diabetes, focusing on the limitations of Hemoglobin A1c (A1C) and introducing glycated albumin (GA) as a complementary indicator. The article aims to provide useful information for the effective usage of GA and other glycemic control markers, outlining both their similarities and differences.